{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:14:28Z","timestamp":1790460868051,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82101711"],"award-info":[{"award-number":["No. 82101711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Context<\/jats:title>\n                <jats:p>Anti-M\u00fcllerian hormone (AMH) levels are increased in polycystic ovary syndrome (PCOS) patients and are associated with PCOS severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the associations between serum AMH levels and in vitro fertilization (IVF)\/ intracytoplasmic sperm injection (ICSI) outcomes in patients with PCOS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Data sources<\/jats:title>\n                <jats:p>PubMed, Embase, and the Cochrane Library were searched on 11 July 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study selection<\/jats:title>\n                <jats:p>Studies reporting the association between serum AMH levels and IVF\/ICSI outcomes in PCOS patients were considered for inclusion. The primary outcomes were clinical pregnancy, live birth, and ovarian hyperstimulation syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Data extraction<\/jats:title>\n                <jats:p>Data were extracted using a standardized data extraction form. Study quality was assessed independently by two groups of researchers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Data synthesis<\/jats:title>\n                <jats:p>Nineteen studies were included in this review. Meta-analyses demonstrated that PCOS patients with a serum AMH level within the 75-100<jats:sup>th<\/jats:sup> percentile had a decreased odds\u00a0of clinical pregnancy (OR: 0.77, 95% CI: 0.63\u20130.93) and livebirth (OR: 0.71; 95% CI: 0.58\u20130.87) compared to those within the 0-25<jats:sup>th<\/jats:sup> percentile. An increased AMH level was also correlated with an increased number of oocytes retrieved (SMD: 0.90, 95% CI: 0.30\u20131.51) and a lower odds of\u00a0fertilization (OR: 0.92, 95% CI: 0.87\u20130.98). There was no significant difference in the number of MII oocytes (SMD: 1.85, 95% CI: -1.07\u20134.78), E<jats:sub>2<\/jats:sub> on the day of hCG (SMD: 0.12; 95% CI: -0.98\u20131.23), or implantation (OR: 0.82, 95% CI: 0.28\u20132.39) between the two groups. In addition, we found significant dose\u2013response associations between serum AMH level and clinical pregnancy, live birth,\u00a0number of oocytes retrieved, and fertilization in PCOS patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>AMH may have clinical utility in counseling regarding IVF\/ICSI outcomes among women with PCOS who wish to undergo fertility treatment. More large-scale, high-quality cohort studies are needed to confirm these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-023-01153-y","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T07:01:49Z","timestamp":1698044509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Association between serum AMH levels and IVF\/ICSI outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Tianyi","family":"Yuwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guhao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengchen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"1153_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bpobgyn.2016.03.004","volume":"37","author":"P Bhide","year":"2016","unstructured":"Bhide P, Homburg R. Anti-M\u00fcllerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:38\u201345.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1153_CR2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","volume":"10","author":"AE Joham","year":"2022","unstructured":"Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, Boyle J, Teede HJ. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10:668\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1153_CR3","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","volume":"2","author":"R Azziz","year":"2016","unstructured":"Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.","journal-title":"Nat Rev Dis Primers"},{"key":"1153_CR4","volume":"25","author":"X Zheng","year":"2022","unstructured":"Zheng X, Wang CC. Is polycystic ovary syndrome undervalued in China? Lancet Reg Health West Pac. 2022;25: 100513.","journal-title":"Lancet Reg Health West Pac"},{"key":"1153_CR5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4067\/S0034-98872012000700015","volume":"140","author":"T Sir-Petermann","year":"2012","unstructured":"Sir-Petermann T. Ladr\u00f3n de Guevara A, Villarroel AC, Preisler J, Echibur\u00fa B, Recabarren S: [Polycystic ovary syndrome and pregnancy]. Rev Med Chil. 2012;140:919\u201325.","journal-title":"Rev Med Chil"},{"key":"1153_CR6","first-page":"Cd006105","volume":"12","author":"LO Tso","year":"2020","unstructured":"Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12:Cd006105.","journal-title":"Cochrane Database Syst Rev"},{"key":"1153_CR7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s13224-020-01362-0","volume":"70","author":"L Shrikhande","year":"2020","unstructured":"Shrikhande L, Shrikhande B, Shrikhande A. AMH and Its Clinical Implications. J Obstet Gynaecol India. 2020;70:337\u201341.","journal-title":"J Obstet Gynaecol India"},{"key":"1153_CR8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humrep\/der446","volume":"27","author":"SM Nelson","year":"2012","unstructured":"Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-M\u00fcllerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012;27:631\u20136.","journal-title":"Hum Reprod"},{"key":"1153_CR9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tem.2019.04.006","volume":"30","author":"H Teede","year":"2019","unstructured":"Teede H, Misso M, Tassone EC, Dewailly D, Ng EH, Azziz R, Norman RJ, Andersen M, Franks S, Hoeger K, et al. Anti-M\u00fcllerian Hormone in PCOS: a review informing international guidelines. Trends Endocrinol Metab. 2019;30:467\u201378.","journal-title":"Trends Endocrinol Metab"},{"key":"1153_CR10","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/humrep\/del421","volume":"22","author":"A La Marca","year":"2007","unstructured":"La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A. Anti-M\u00fcllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22:766\u201371.","journal-title":"Hum Reprod"},{"key":"1153_CR11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1471-0528.2005.00670.x","volume":"112","author":"S Muttukrishna","year":"2005","unstructured":"Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005;112:1384\u201390.","journal-title":"BJOG"},{"key":"1153_CR12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rbmo.2016.04.007","volume":"33","author":"D Garg","year":"2016","unstructured":"Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016;33:15\u201328.","journal-title":"Reprod Biomed Online"},{"key":"1153_CR13","volume":"12","author":"Y Guo","year":"2021","unstructured":"Guo Y, Liu S, Hu S, Li F, Jin L. High serum anti-mullerian hormone concentrations are associated with poor pregnancy outcome in fresh IVF\/ICSI cycle but not cumulative live birth rate in PCOS patients. Front Endocrinol (Lausanne). 2021;12: 673284.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1153_CR14","doi-asserted-by":"crossref","unstructured":"Arslanca T, Ecemis T, Kiseli M, Arslanoglu E, Kotanoglu MS, Caglar GS: Pregnancy outcome of freeze thaw cycles of polycystic ovary syndrome patients regarding the anti-Mullerian hormone percentile. J Obstet Gynaecol. 2021:1\u20136.","DOI":"10.1080\/01443615.2021.1962819"},{"key":"1153_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12958-020-00581-4","volume":"18","author":"R Tal","year":"2020","unstructured":"Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reprod Biol Endocrinol. 2020;18:20.","journal-title":"Reprod Biol Endocrinol"},{"key":"1153_CR16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10815-012-9726-x","volume":"29","author":"W Xi","year":"2012","unstructured":"Xi W, Gong F, Lu G. Correlation of serum Anti-M\u00fcllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients. J Assist Reprod Genet. 2012;29:397\u2013402.","journal-title":"J Assist Reprod Genet"},{"key":"1153_CR17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700.","journal-title":"BMJ"},{"key":"1153_CR18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787\u20138.","journal-title":"JAMA Surg"},{"key":"1153_CR19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/09513590.2013.769519","volume":"29","author":"S Sahmay","year":"2013","unstructured":"Sahmay S, Guralp O, Aydogan B, Cepni I, Oral E, Irez T. Anti-Mullerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients. Gynecol Endocrinol. 2013;29:440\u20133.","journal-title":"Gynecol Endocrinol"},{"key":"1153_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12884-022-04518-0","volume":"22","author":"S Liu","year":"2022","unstructured":"Liu S, Hong L, Mo M, Xiao S, Wang X, Fan X, Zhang S, Diao L, Zeng Y. Association of antimullerian hormone with polycystic ovarian syndrome phenotypes and pregnancy outcomes of in vitro fertilization cycles with fresh embryo transfer. BMC Pregnancy Childbirth. 2022;22:171.","journal-title":"BMC Pregnancy Childbirth"},{"key":"1153_CR21","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.fertnstert.2009.12.002","volume":"94","author":"C Kaya","year":"2010","unstructured":"Kaya C, Pabuccu R, Satiroglu H. Serum antimullerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. Fertil Steril. 2010;94:2202\u20137.","journal-title":"Fertil Steril"},{"key":"1153_CR22","volume":"12","author":"M Du","year":"2021","unstructured":"Du M, Zhang J, Yu X, Guan Y. Elevated anti-mullerian hormone is an independent risk factor for preterm birth among patients with overweight polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12: 788000.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"444\u2013452","key":"1153_CR23","volume":"113","author":"KL Hu","year":"2020","unstructured":"Hu KL, Liu FT, Xu H, Li R, Qiao J. High antimullerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome. Fertil Steril. 2020;113(444\u2013452): e441.","journal-title":"Fertil Steril"},{"key":"1153_CR24","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1210\/jc.2018-01320","volume":"103","author":"JY Hsu","year":"2018","unstructured":"Hsu JY, James KE, Bormann CL, Donahoe PK, P\u00e9pin D, Sabatini ME. M\u00fcllerian-inhibiting substance\/Anti-M\u00fcllerian hormone as a predictor of preterm birth in polycystic ovary syndrome. J Clin Endocrinol Metab. 2018;103:4187\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"1153_CR25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.51441\/BioMedica\/5-350","volume":"37","author":"J Du","year":"2021","unstructured":"Du J, Cao Y. Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing In vitro fertilization-embryo transfer. BioMedica. 2021;37:240\u20137.","journal-title":"BioMedica"},{"key":"1153_CR26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.29252\/ijrm.16.8.483","volume":"16","author":"N Tabibnejad","year":"2018","unstructured":"Tabibnejad N, Soleimani M, Aflatoonian A. Serum Anti-Mullerian hormone and embryo morphokinetics detecting by time-lapse imaging: a comparison between the polycystic ovarian syndrome and tubal factor infertility. Int J Reprod Biomed. 2018;16:483\u201390.","journal-title":"Int J Reprod Biomed"},{"key":"1153_CR27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13048-018-0445-5","volume":"11","author":"VNA Ho","year":"2018","unstructured":"Ho VNA, Pham TD, Le AH, Ho TM, Vuong LN. Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome. J Ovarian Res. 2018;11:70.","journal-title":"J Ovarian Res"},{"key":"1153_CR28","volume":"12","author":"Y Guan","year":"2021","unstructured":"Guan Y, Kong P, Xiao Z, Zhang J, He J, Geng W, Yan J, Sun S, Mu M, Du X, Wang X. Independent variables for determining the cumulative live birth rates of aged patients with polycystic ovary syndrome or tubal factor infertility: a retrospective cohort study. Front Endocrinol (Lausanne). 2021;12: 728051.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1153_CR29","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/0300060517704140","volume":"45","author":"Y Chen","year":"2017","unstructured":"Chen Y, Ye B, Yang X, Zheng J, Lin J, Zhao J. Predicting the outcome of different protocols of in vitro fertilization with anti-Mu\u00fcllerian hormone levels in patients with polycystic ovary syndrome. J Int Med Res. 2017;45:1138\u201347.","journal-title":"J Int Med Res"},{"key":"1153_CR30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12905-022-01756-4","volume":"22","author":"R Muharam","year":"2022","unstructured":"Muharam R, Prasetyo YD, Prabowo KA, Putri YI, Maidarti M, Hestiantoro A. IVF outcome with a high level of AMH: a focus on PCOS versus non-PCOS. BMC Womens Health. 2022;22:172.","journal-title":"BMC Womens Health"},{"key":"1153_CR31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4103\/0256-4947.71063","volume":"30","author":"S Arabzadeh","year":"2010","unstructured":"Arabzadeh S, Hossein G, Rashidi BH, Hosseini MA, Zeraati H. Comparing serum basal and follicular fluid levels of anti-M\u00fcllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome. Ann Saudi Med. 2010;30:442\u20137.","journal-title":"Ann Saudi Med"},{"key":"1153_CR32","doi-asserted-by":"crossref","unstructured":"Acharya KS, Harris BS, Weber JM, Truong T, Pieper C, Eaton JL: Impact of increasing antim\u00fcllerian hormone level on in\u00a0vitro fertilization fresh transfer and live birth rate. F&S Reports. 2022.","DOI":"10.1016\/j.xfre.2022.06.005"},{"key":"1153_CR33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/14767058.2016.1272567","volume":"31","author":"A Kamel","year":"2018","unstructured":"Kamel A, Ramadan W, Hussein AM, Dahab S, Elsherbini MM, Lasheen YS, Abu-Hamila F. Can AMH levels predict the need for increased medication during IVF\/ICSI in PCOS women? J Matern Fetal Neonatal Med. 2018;31:32\u20138.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"1153_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.fertnstert.2014.09.041","volume":"103","author":"R Tal","year":"2015","unstructured":"Tal R, Tal O, Seifer BJ, Seifer DB. Antim\u00fcllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril. 2015;103:119\u2013130.e113.","journal-title":"Fertil Steril"},{"key":"1153_CR35","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1210\/jc.2008-1231","volume":"93","author":"S Catteau-Jonard","year":"2008","unstructured":"Catteau-Jonard S, Jamin SP, Leclerc A, Gonzal\u00e8s J, Dewailly D, di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:4456\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"1153_CR36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/jc.2006-1582","volume":"92","author":"L Pellatt","year":"2007","unstructured":"Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H. Granulosa cell production of anti-M\u00fcllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92:240\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1153_CR37","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/humrep\/der297","volume":"26","author":"D Dewailly","year":"2011","unstructured":"Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26:3123\u20139.","journal-title":"Hum Reprod"},{"key":"1153_CR38","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1093\/humrep\/dep225","volume":"24","author":"LG Nardo","year":"2009","unstructured":"Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009;24:2917\u201323.","journal-title":"Hum Reprod"},{"key":"1153_CR39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","volume":"132","author":"R Azziz","year":"2018","unstructured":"Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132:321\u201336.","journal-title":"Obstet Gynecol"},{"key":"1153_CR40","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.fertnstert.2014.09.012","volume":"102","author":"D Llaneza-Suarez","year":"2014","unstructured":"Llaneza-Suarez D, Llaneza P, Gonz\u00e1lez C, De-La-Fuente P, Garc\u00eda-Ochoa C, Garrido P, Casta\u00f1\u00f3n V, P\u00e9rez-L\u00f3pez FR. Assessment of follicular fluid leptin levels and insulin resistance as outcome predictors in women undergoing in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril. 2014;102:1619\u201325.","journal-title":"Fertil Steril"},{"key":"1153_CR41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40618-020-01209-5","volume":"43","author":"L Gao","year":"2020","unstructured":"Gao L, Li M, Wang Y, Zeng Z, Xie Y, Liu G, Li J, Zhang B, Liang X, Wei L, Yang X. Overweight and high serum total cholesterol were risk factors for the outcome of IVF\/ICSI cycles in PCOS patients and a PCOS-specific predictive model of live birth rate was established. J Endocrinol Invest. 2020;43:1221\u20138.","journal-title":"J Endocrinol Invest"},{"key":"1153_CR42","doi-asserted-by":"crossref","first-page":"19750","DOI":"10.1038\/s41598-020-76543-y","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Wang Y, Yang H, Gao T, Yu C, Cao F, Xia X, Wu J, Zhou X, Chen L. AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF\/ICSI cycles. Sci Rep. 2020;10:19750.","journal-title":"Sci Rep"},{"key":"1153_CR43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/uog.15898","volume":"48","author":"M Kollmann","year":"2016","unstructured":"Kollmann M, Martins WP, Lima ML, Craciunas L, Nastri CO, Richardson A, Raine-Fenning N. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2016;48:709\u201318.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"59","key":"1153_CR44","first-page":"e51","volume":"211","author":"R Tal","year":"2014","unstructured":"Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antim\u00fcllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(59):e51\u201358.","journal-title":"Am J Obstet Gynecol"},{"key":"1153_CR45","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10815-011-9627-4","volume":"28","author":"P Ocal","year":"2011","unstructured":"Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-M\u00fcllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011;28:1197\u2013203.","journal-title":"J Assist Reprod Genet"},{"key":"1153_CR46","doi-asserted-by":"crossref","unstructured":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016, 106:1634\u20131647.","DOI":"10.1016\/j.fertnstert.2016.08.048"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01153-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:31:22Z","timestamp":1700339482000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01153-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01153-y","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}